Contrast-induced acute kidney injury (CI-AKI) following intra-arterial administration of iodinated contrast media

Journal of Nephrology

Volumn 23, Issue 6, 2010, Pages 658-666

  Karlsberg, Ronald P ^a   Dohad, Suhail Y ^a   Sheng, Rubin ^b  

^a Cardiovascular Research Foundation of Southern California   (United States)

^b GE HEALTHCARE   (United States)

Author keywords

Contrast induced acute kidney injury (CI AKI); Intra arterial digital subtraction angiography; Iodixanol; Low osmolar contrast media; Peripheral arterial occlusive disease; Serum creatinine

Indexed keywords

CREATININE; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; IOVERSOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST INDUCED ACUTE KIDNEY INJURY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; FEMALE; HUMAN; ILIAC ARTERY; LEG ARTERY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANGIOGRAPHY, DIGITAL SUBTRACTION; CONTRAST MEDIA; CREATININE; FEMALE; HUMANS; IOPAMIDOL; MALE; MIDDLE AGED; TRIIODOBENZOIC ACIDS;

EID: 78549267514     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation. 2006;113:1799-1806. (Pubitemid 43958473)
2. Aspelin P, Aubry P, Fransson S-G, Strasser R, Willenbrock R, Berg KJ; NEPHRIC Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-499. (Pubitemid 36159884)
3. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol. 1999;72:701-703. (Pubitemid 29355616)
4. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography. The RECOVER Study: a randomized controlled trial. J Am Coll Cardiol. 2006;48:924-930.
5. Nguyen SA, Suranyi P, Ravenel J, et al. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology. 2008;248:97-105.
6. Nie B, Cheng WJ, Li YF, et al. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Catheter Cardiovasc Interv. 2008;72:958-965.
7. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF; for the VALOR Trial Investigators. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) trial. Am J Heart. 2008;156:776-782.
8. Hardiek KJ, Katholi RE, Robbs RS, Katholi CE. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabetes Complications. 2008;22:171-177. (Pubitemid 351552047)
9. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol. 2006;41:815-821.
10. Kuhn MJ, Chen N, Sahani DV, et al. The PREDICT Study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. AJR Am J Roentgenol. 2008;191:151-157. (Pubitemid 351955220)
11. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115:3189-3196. (Pubitemid 47012233)
12. Thomsen HS, Morcos SK, Erley CM, et al. The ACTIVE trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43:170-178.
13. Feldkamp T, Baumgart D, Eisner M, et al. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol. 2006;66:322-330. (Pubitemid 44718143)
14. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: Part 1: executive summary. 2002. Available at: http://www.kidney.org/Professionals/ Kdoqi/guidelines-ckd/p1-exec.htm. Accessed April 12, 2010.
15. Mehran R, Aymong ED, Nikolsky E. at al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399.
16. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692-699. (Pubitemid 44175706)
17. McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin. 2005;21:261-280.
18. Hernandez F, Mora L, Suberviola V, et al. Comparison of iodixanol versus ioversol for prevention of contrast induced nephropathy in diabetic patients undergoing coronary angiography or intervention [abstract]. Eur Heart J 2007;28(Abstract Supplement):454.